. 2022 Jun 20;54(1):1686–1700. doi: 10.1080/07853890.2022.2085881

Table 3.

In vitro activity of tetracycline-class drugs in the presence and absence of acquired tetracycline resistance genes [34,98,102,103].

Strain	Tet^R determinant	Mechanism type	MIC range (µg/mL)
			Firstgeneration	Secondgeneration	Third-generation
			Tetracycline^a	Doxycycline^a	Omadacycline^a	Eravacycline^b	Tigecycline^b
Staphylococcus aureus	None	–	≤0.06–0.25	≤0.06–0.125	≤0.06–0.5	0.015–0.12	0.03–0.25
	tet(M)	RPPs	32 to >64	2–16	0.125–1	NR	NR
	tet(K)	Efflux pump	16–32	1–4	0.125–0.25	0.063	0.13
Streptococcus pneumoniae	None	–	≤0.06–0.25	≤0.06–0.25	≤0.06–0.25	0.004–0.03	0.015–0.12
Streptococcus pneumoniae	tet(M)	RPPs	4–64	2–4	≤0.06	0.016	≤0.016
β-hemolytic streptococci^c	None	–	≤0.06–0.125	≤0.06	≤0.06–0.50	0.004–0.25	≤0.008–0.25
	tet(M)	RPPs	4–64	2–16	≤0.06–0.50	NR	NR
	tet(O)	RPPs	32–64	8	≤0.06–0.25	NR	NR

MIC: minimum inhibitory concentration; NR: not recorded; RPP: ribosomal protection protein.

^{^a}

Data for first- and second-generation tetracycline-class drugs and omadacycline adapted from [34].

^{^b}

Data for eravacycline and tigecycline adapted from [98,104,105].

^{^c}

S. pyogenes and S. agalactiae.